Abstract 2043: Circulating tumor DNA (ctDNA) mutation analysis at baseline (BSL) and end of treatment (EOT) with sacituzumab govitecan (SG) and clinical impact on efficacy in patients (pts) with HR+/HER2- metastatic breast cancer (mBC): Biomarker results from TROPiCS-02
Year: 2025
Type: conference-abstract
Source: Cancer Research
Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Gilead Sciences (United States), Heidelberg University, Medizinische Fakultät Mannheim, Queen Mary University of London, Barts Cancer Institute, IDCQ Hospitales y Sanidad, S.L.U., Harvard University, Dana-Farber Cancer Institute, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409627099